Education
About Us
Working with TipRanks
Follow Us
Vir Biotechnology (VIR)
NASDAQ:VIR
VIR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.32 - $14.45
Previous CloseN/A
Volume25.73M
Average Volume (3M)1.04M
Market Cap
$695.34M
Enterprise Value$97.08M
Total Cash (Recent Filing)$801.66M
Total Debt (Recent Filing)$96.09M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Aug 06, 2025EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding138,238,000
10 Day Avg. Volume807,918
30 Day Avg. Volume1,043,491
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.14
Enterprise Value/Revenue4.95
Enterprise Value/Gross Profit7.20
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$16.86Price Target Upside235.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Chronic Hepatitis Delta Virus ProgramVir has successfully initiated its Phase 3 ECLIPSE program in chronic hepatitis delta, marking a significant milestone as they aim to develop a potential new standard of care for this high unmet need indication.
Financial PositionWith approximately $1.02B in cash and runway into mid-2027, full ownership of its key assets, and catalysts across both CHD and oncology, Vir is entering a more focused and potentially more investable phase of its lifecycle.
Oncology ProgramVir's T-cell engager (TCE) in oncology programs are progressing well, with VIR-5818 and VIR-5500 showing early efficacy and safety signals in solid tumors.
Bears Say
Hepatitis B Virus ProgramThe updated 24-week off-treatment data from the Phase 2 program (MARCH) did not meet functional cure thresholds needed to support a Phase 3 investment in the absence of a global partner in chronic hepatitis B virus (CHB).
Market CompetitionPasritamig's safety profile could challenge VIR-5500's competitive positioning, with only 9% Grade 1 CRS at RP2D compared to VIR-5500's 25% low-grade CRS rate.
Partnership ChallengesThe prospects for a larger HBV partnership could be more challenging due to the recent data results.
Vir Biotechnology News
VIR FAQ
What was Vir Biotechnology’s price range in the past 12 months?
Vir Biotechnology lowest stock price was $4.32 and its highest was $14.45 in the past 12 months.
What is Vir Biotechnology’s market cap?
Vir Biotechnology’s market cap is $695.34M.
When is Vir Biotechnology’s upcoming earnings report date?
Vir Biotechnology’s upcoming earnings report date is Aug 06, 2025 which is in 2 days.
How were Vir Biotechnology’s earnings last quarter?
Vir Biotechnology released its earnings results on May 07, 2025. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.836 by -$0.044.
Is Vir Biotechnology overvalued?
According to Wall Street analysts Vir Biotechnology’s price is currently Undervalued.
Does Vir Biotechnology pay dividends?
Vir Biotechnology does not currently pay dividends.
What is Vir Biotechnology’s EPS estimate?
Vir Biotechnology’s EPS estimate is -0.72.
How many shares outstanding does Vir Biotechnology have?
Vir Biotechnology has 138,238,000 shares outstanding.
What happened to Vir Biotechnology’s price movement after its last earnings report?
Vir Biotechnology reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.836. Following the earnings report the stock price went down -3.565%.
Which hedge fund is a major shareholder of Vir Biotechnology?
Currently, no hedge funds are holding shares in VIR
Vir Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.86 (235.19% Upside)
$16.86 (235.19% Upside)
Blogger Sentiment
Bullish
VIR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 136.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $37.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.30%
12-Months-Change
Fundamentals
Return on Equity
-44.59%
Trailing 12-Months
Asset Growth
-27.10%
Trailing 12-Months
Company Description
Vir Biotechnology
Vir Biotechnology, Inc. is a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. It operates within the biotechnology sector, primarily targeting viral infections such as influenza, hepatitis B, and COVID-19. The company specializes in developing innovative therapeutics, including monoclonal antibodies, small interfering ribonucleic acid (siRNA), and vaccines aimed at enhancing the immune system's ability to combat these diseases.
VIR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted several significant achievements such as the initiation of the ECLIPSE Phase III program, a strong financial position, and positive updates in the oncology portfolio. However, these were tempered by financial losses, strategic challenges with Alnylam, and dependency on partnerships for the hepatitis B program's progress.Read More>VIR Stock 12 Month Forecast
Average Price Target
$16.86
▲(235.19%Upside)
Technical Analysis
Spyre Therapeutics
―
Intellia Therapeutics
―
Arcus Biosciences
―
Nurix Therapeutics
―
Pharvaris
―
Ownership Overview
5.15% Insiders
15.58% Mutual Funds
0.04% Other Institutional Investors
58.53% Public Companies and
Individual Investors